Imatinib 120 capsules 100mg Imatinib mesylate Cancer Иматиниб Виста

Imatinib Indications

- adults and children with the newly diagnosed positive (Ph +) (with a Philadelphia chromosome leukocyte (bcr-abl)) chronic myelogenous leukemia (CML) for which bone marrow transplantation is not considered as the first line of therapy;
- adults and children with Ph + -CHL in the chronic phase after failure of interferon alpha therapy or in the acceleration phase, or in the phase of blast crisis;
- in the chemotherapy of adults and children with the first diagnosis of positive acute lymphoblastic leukemia (Ph + GLL) with the presence of Philadelphia chromosomes in leukocytes;
- as monotherapy in adult patients with acute lymphocytic leukemia (Ph + GLL) in the relapse or difficult to treat;
- adult patients with myelodysplastic / myeloproliferative diseases (MDS / MPD) associated with the restructuring of the platelet-derived growth factor receptor gene (TGF);
- adults with hyper-oesinophilic syndrome (HES) and / or chronic eosinophilic leukemia (HEL) with gene rearrangement of FIP1L1-PDGFRα.

- treatment of adult patients with Kit (CD117) -positive inoperable and / or metastatic malignant gastrointestinal stromal tumors (GIST);
- adjuvant therapy in adult patients with a high risk of recurrence of Kit (CD117) -positive malignant gastrointestinal stromal tumors (GIST) after resection. Patients with low or minimal risk may not receive adjuvant therapy;
- treatment of adult patients with inoperable dermatophyrosarcoma protuberans (DFSP) and adult patients with recurrent and / or metastatic dermatophyrosis (DFSP) that can not be surgically removed.

Contradictions

Hypersensitivity to the active substance or any other component of the medicament.

Dosage & Administration

Therapy should be conducted by a physician experienced in the treatment of patients with malignant neoplasms of blood and malignant sarcomas depending on the nosology.